NCT00003645View on ClinicalTrials.gov

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

PHASE3TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 14, 1999

Primary Completion Date

March 20, 2017

Study Completion Date

March 20, 2017

Conditions
Prostate Cancer
Interventions
DRUG

Flutamide

10.8 mg intramuscularly once every 3 months for 12 months

DRUG

Leuprolide Acetate

50 mg tablet orally daily for 12 months

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eastern Cooperative Oncology Group

NETWORK

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER